drugset / Trial / NCT07292012
Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Phase 4
Recruiting
75 enrolled
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
NaSingle-groupOpen-labelSupportive care
Summary
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Timeline
- Start
- 2026-05-11
- Primary completion
- 2027-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | 300 mg | Intravenous |